RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase not stated

Registered title, quoted from ClinicalTrials.gov

NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Henan Cancer Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06781281, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Pathologically proven HR+/HER2- breast cancer:

    Inclusion criterion 3

  3. ECOG score≤1 point;

    Inclusion criterion 10

  4. Females of childbearing age, with a negative serum pregnancy test 14 days before randomization;

    Inclusion criterion 9

    pregnant or breastfeeding women;

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06781281, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age>=18 years old
  • cT2 - cT4d, or cT1c with axillary lymph node metastasis confirmed clinically and pathologically;
  • Pathologically proven HR+/HER2- breast cancer:

defined as:

  • positive for ER or PR (IHC nuclear staining >1%)
  • Her-2 negative (IHC 0, 1+ without FISH, or IHC 2+ with no amplification by FISH);
  • Has clinically measurable lesions:Measurable lesions on ultrasound, mammography, or MR (optional) within 1 month before randomization;
  • Organ and bone marrow function tests within 1 month before chemotherapy suggest no contraindications to chemotherapy;
  • Cardiac ultrasound EF value ≧55%;
  • Females of childbearing age, with a negative serum pregnancy test 14 days before randomization;
  • ECOG score≤1 point;
  • Sign informed consent;

Exclusion Criteria:

  • The patient has evidence of metastatic breast cancer;
  • For this disease, chemotherapy, endocrine therapy, targeted therapy, radiation therapy, etc. have been received;
  • The patient has a second primary malignancy other than adequately treated skin cancer;
  • The patient has been treated with anti-programmed cell death protein 1 (anti-PD-1), anti-programmed death ligand 1 (anti-PD-L1) or anti-PD-L2 drugs, or other immunotherapy;
  • The patient has been diagnosed with immunodeficiency disease or autoimmune disease;
  • The patient has severe lung or heart disease;
  • The patient has active hepatitis B and C;
  • The patient has a history of organ transplantation or bone marrow transplantation;
  • pregnant or breastfeeding women;
  • The investigators considered chemotherapy contraindicated due to serious, uncontrolled other medical conditions.

Quoted from ClinicalTrials.gov, NCT06781281, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06781281, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06781281